Background: Axillary lymph node staging is traditionally important to provide prognostic information to guide further treatment. However, the relevance of isolated tumour cells (ITC) or micrometastases in axillary nodes and the need for adjuvant treatment remain uncertain.
introduction
Axillary lymph node staging is traditionally important to provide prognostic information to guide adjuvant radiotherapy and systemic treatment in patients with early breast cancer. Sentinel node biopsy (SNB) is generally accepted as a safe method for predicting axillary lymph node involvement, which prevents an invasive complete axillary lymph node dissection (ALND) in patients with a negative SNB biopsy [1] [2] [3] [4] [5] [6] . Further lymph node involvement is a strong indicator for the prognosis of the patient. With the introduction of the SNB and immunohistochemical staining, the detection of isolated tumour cells (ITC and pN0i+) and micrometastases ( pN1mi) has increased [7, 8] .
This additional knowledge has led to some uncertainties and debates: in case of ITC or micrometastases, what is the risk of further nodal involvement in the axilla? Does this information have any prognostic relevance and, if yes, to what extent? And finally, is standard adjuvant treatment required?
Some studies report that minimal lymph node involvement is associated with poorer prognosis [9] [10] [11] [12] . Other studies do not find differences in disease-free and overall survival of patients with ITC or micrometastases versus node-negative patients [13] [14] [15] . Subsequently, implications for further treatment of patients with ITC or micrometastases vary between studies (e.g. complete ALND and/or adjuvant systemic therapy). A large cohort study (MIRROR) reported that patients with ITC or micrometastases had a significantly worse 5-year disease-free survival, and those with ITC or micrometastases who were treated with adjuvant systemic therapy had better survival rates [16] . Another study, based on the data from seven hospitals ( partially the same cohort as the MIRROR study), reported no substantial impact of micrometastases on overall survival during the first 5 years after diagnosis. These authors postulate that micrometastatic disease itself should not be an indication for adjuvant systemic therapy [15] .
The Netherlands Cancer Registry (NCR) records all new cancers occurring in the Netherlands. The current study, which uses NCR data on breast cancer patients diagnosed between 2003 and 2006 with the completion of 5-year follow-up, aims to add valuable data to guide the before-mentioned discussion.
The aim of this study was to examine the prognosis of breast cancer patients with ITC or micrometastases while thoroughly accounting for all other prognostically relevant clinical variables and to study the effect of adjuvant systemic therapy in an unselected population-based cohort of patients.
patients and methods
The NCR is a nationwide, population-based cancer registry with information on tumour characteristics and treatment. PALGA, the Dutch network and registry of all pathological diagnoses, notifies the NCR of all newly diagnosed malignancies. Following this notification, trained registrars actively record data on diagnosis, staging and treatment directly from the patient's medical records, including pathology and surgery reports. Primary treatment is coded in the sequence of administration, and patients are staged according to the TNM system of the International Union Against Cancer [17] .
From the NCR, all female breast cancer patients diagnosed between 1 January 2003 and 31 December 2006 who had a pT1-2 tumour, no macrometastases in axillary nodes (thus including pN0, pN0i+ and pN1mi) and no distant metastases, who had no history of cancer and no bilateral breast cancer, were selected.
Patient and tumour characteristics [age at diagnosis, pathological tumour size ( pT), nodal status ( pN), histological grade according to the Bloom and Richardson grading system, histological subtype, multifocality (separate foci of carcinoma in one or multiple quadrants), hormone receptor status (estrogen receptor (ER) and progesterone receptor (PgR)) and her2 status], information on treatment (type of breast surgery, method of axillary staging, radiotherapy, chemotherapy, hormonal therapy and trastuzumab), were extracted. Clinical follow-up data (recurrence of disease, occurrence of other cancer and vital status) were collected for all patients 5 years after diagnosis.
We aimed to focus on the prognosis of patients with ITC or micrometastases and the effect of adjuvant systemic therapy in this specific subgroup. Therefore, we excluded patients with unfavourable tumour characteristics (grade 3 tumours sized >1 cm), who would have been eligible for adjuvant treatment based on primary tumour characteristics alone. We also excluded patients who received neoadjuvant therapy or were not treated with curative intent [no surgery, no axillary staging (SNB and/or ALND) or had macroscopic tumour residue after final surgery]. And finally, we excluded patients without follow-up data.
classification of axillary lymph node involvement
From the 6th edition of the TNM staging system onwards, ITC are included in the IUCC coding system [17] . ITC are defined as 'single cells or small clusters of cells (≤0.2 mm)' that are usually detected with immunohistochemistry staining. Axillary nodes with ITC are considered to be cancer-negative and coded as pN0i+. Micrometastases are slightly larger with a diameter between 0.2 and 2.0 mm and are considered node positive and coded as pN1mi.
end points
The primary end point was 5-year disease-free survival, using a composite end point (locoregional recurrence, distant metastases or contralateral breast cancer). The secondary end point was a composite end point consisting of either locoregional recurrence or distant metastases. Patients were censored at date of death or date of diagnosis of a second malignancy other than breast cancer. Survival time was defined as time between date of diagnosis up to any of the above end points whichever occurred first, and the date until a patient was lost to follow-up.
We chose not to report on overall survival, for the follow-up period of 5 years is to short to examine overall survival. Even when diagnosed with distant metastases or contralateral breast cancer during our follow-up period, most of the patients will survive for many more years. Breast cancerspecific survival might be of interest. However, the NCR registers no data on the causes of death.
statistical analysis
Patient and tumour characteristics are presented as means (continuous data) or percentages. The χ 2 test was used to evaluate differences in categorical variables. Multivariate Cox proportional hazards regression was used to assess the prognostic significance of ITC and micrometastases on disease-free survival, independent of other prognostic factors that were selected based on significance in univariate analyses (P < 0.1). The prognostic factors included were age (continuous), tumour size ( pT1mi, pT1A, pT1B, pT1C and pT2), grade (I, II, III and unknown), receptor status (ER or PgR positive, ER and PgR negative), the type of final surgery (breast-conserving surgery and mastectomy), SNB (yes and no), ALND (yes and no) radiotherapy (yes and no), chemotherapy (yes and no), hormonal therapy (yes and no) and her2 status combined with treatment (her2 negative, her2 positive without trastuzumab, her2 positive with trastuzumab and her2 unknown).
We imputed missing values (grade 1645 missings, 9.0%; receptor status 4166 missings, 22.7%; multifocality 5145 missings, 28.0% and SNB 1458 missings, 7.9%) with a multiple imputation procedure in which each missing value was imputed 20 times. We did not impute her2 status and tumour residue after the final surgery (her2 was not routinely assessed during our study period and tumour residue was not significant in univariate analyses). Values were imputed based on the predictive distribution in an imputation model that included risk factors and outcomes. This procedure resulted in 20 complete datasets. All analyses were carried out on both the complete case dataset and the multiple imputation sets. Results reported are based on the multiple imputed data.
We compared disease-free survival among node-negative patients, and those with ITC or micrometastases. We also examined whether chemo-and hormonal treatment were effective after adjustment for other patient and tumour characteristics that are associated with disease-free survival. We also tested for interaction between adjuvant treatment and pN.
All analyses were carried out using STATA (version 12.0; StataCorp, College Station, TX, USA).
results
A total of 18 748 patients were diagnosed with pT1-2, pN0-pN1mi, M0 breast cancer over the period 2003-2006 and met our inclusion criteria. Of these patients, 378 (2.0%) were excluded due to incomplete follow-up data, leaving 18 370 patients who were included in our analyses.
Patient and tumour characteristics are summarized in Table 1 . Node-negative patients generally had smaller and more often well-differentiated tumours, compared with those with Annals of Oncology original articles Treatment varied substantially between the groups: nodenegative patients were treated with breast-conserving surgery (combined with radiotherapy) more frequently. Complete ALND occurred more in patients with ITC or micrometastases than in node-negative patients (50%, 81% and 23%, respectively). The proportion of patients with complete ALND following a SNB procedure remained stable over time for patients with micrometastases, but decreased for patients with node-negative diseases and ITC (from 35% to 14% in nodenegative disease and from 69% to 38% in ITC in 2003 and 2006, respectively). The proportion of patients receiving systemic adjuvant treatment is related to nodal stage: hormonal therapy was administered to 15%, 32% and 62% of the patients with node-negative, ITC and micrometastases, respectively. Chemotherapy was administered to 7%, 14% and 32% of these patients, respectively. Only a minority of patients included in the present analysis received adjuvant trastuzumab.
The median follow-up was 5 years (mean 4.3 years, range 0.1-5.0 years; total 81 399 years of observation). Table 2 summarizes the number of events according to pN. Five-year primary end point for all women was 89.9% [95% confidence interval (CI) 89.5% to 90.4%]; it was 90.0%, 89.2% and 89.7% for patients with node-negative disease, ITC and micrometastases, respectively. The crude, unadjusted risk for disease-free survival did not differ between these three groups; the hazard ratio (HR) was 1.09 (95% CI 0.86-1.39) and 1.04 (95% CI 0.88-1.22) for patients with ITC or micrometastases versus node-negative patients, respectively. Composite end point including locoregional recurrence and distant metastases.
Annals of Oncology original articles
After adjusting for prognostic factors (including treatment), patients with ITC had comparable risks as node-negative patients (HR = 1.12, n.s. and HR = 1.20, n.s. for primary and secondary end points, respectively; Table 3 ). Patients with micrometastases had a 38%-50% higher risk (HR = 1.38, sign. and 1.50, sign., respectively). In separate analyses of patients who did not receive any kind of systemic therapy comparable results were seen (data not shown).
Other tumour characteristics with a prognostic value are larger tumour size, higher grade, multifocality and negative receptor status, with comparable results for primary and secondary end points ( Figure 1A and B) .
Chemotherapy reduced the primary event risk for all patients (HR 0.74; 95% CI 0.60-0.92). The effect of hormonal treatment was determined by pN. The reduction of the event risk in case of hormonal therapy was 66% in patients with micrometastases (HR 0.34; 95% CI 0.23-0.51) and 46% and 54% in patients with node-negative disease or ITC (HR 0.54; 95% CI 0.45-0.65 and HR 0.46; 95% CI 0.25-0.86, respectively). These results were comparable in analyses of the secondary end point. No interaction was found between pN and chemotherapy.
discussion
We found that the prognosis of patients with ITC did not differ significantly from that of patients with node-negative disease in a large unselected population. Patients with micrometastases, however, had a significantly worse prognosis, with a 38% higher risk of locoregional recurrence, distant metastases or contralateral breast cancer within 5 years after diagnosis. Furthermore, we demonstrated that all patients benefitted from adjuvant systemic treatment (chemotherapy and hormonal treatment), and those with micrometastases seemed to derive more benefit from hormonal therapy than those with ITC or node-negative disease.
The results of our study differ from the findings of the Dutch MIRROR study that found that the prognostic significance of ITC is comparable to micrometastases (HR 1.50 and 1.56 for ITC versus node-negative and micrometastases versus nodenegative, respectively). The MIRROR study selected the nodenegative cohort from patients diagnosed over the period 2000-2001 and the ITC and micrometastases cohorts over 1997-2005. Apart from the fact that our study concerns more recent years of diagnosis for all patients (2003-2006), we have no explanation for the difference in findings. However, other studies have reported no worse overall or disease-free survival for patients with micrometastases [13 -15] . The number of events in these studies was relatively small, thus possibly obscuring a small effect. The results from the large NSABP trial B-32 are comparable to our findings, with HR of 1.18 and 1.38 for ITC and micrometastases on disease-free survival [12] . Data from the SEER database also show similar results on overall survival for pN1mi patients [10] .
complete axillary lymph node dissection following sentinel node biopsy Recent large studies show that complete ALND after SNB has no additional benefit on regional control and overall survival for patients with ITC or those with micrometastases who receive adjuvant systemic therapy [18] [19] [20] [21] [22] [23] . In the USA, data from the National Cancer Database show 45% of patients with micrometastases who did not undergo ALND in 2005 [24] . In our study, the percentage of ALND is 80% for patients with micrometastases, and this did not drop over the study period up to 2006. Further analyses on more recent data will give more insights in current practice, as it is expected that this percentage will drop for patients with micrometastases, as it did for ITC.
adjuvant treatment
Debate currently focuses on the benefits of adjuvant therapy in patients with micrometastases in axillary lymph nodes. The MIRROR study reported a lower 5-year disease-free survival rate of nearly 10% in patients with ITC or micrometastases when receiving systemic adjuvant chemotherapy, with adjusted HR of 0.66 (95% CI 0.46-0.95) and 0.50 (95% CI 0.35-0.72), respectively. Our study differentiates between adjuvant chemotherapy and hormonal treatment. All patients benefit from additional adjuvant treatment. We observed that patients with micrometastases benefit to a larger extent from hormonal therapy than those with node-negative disease.
Based on the results of the MIRROR study, discussions started on whether to consider adjuvant chemotherapy based only on the presence of ITC or micrometastases in the axilla. However, we are reluctant to advise chemotherapy in all patients with ITC or micrometastases, particularly in those who have no aggressive tumour characteristics. The disease-free survival is already good, which makes the potential benefit from chemotherapy small; while side-effects of chemotherapy are considerable. Furthermore, it is likely that genomic primary tumour characteristics will tell more about the propensity of dissemination from the primary cancer rather than the status of the axillary lymph nodes. Reported HRs on 5-year distant metastases-free survival for three genetic signatures (high versus low risk) vary from 3.4 to 7.1 [25] . Treatment decisions in these patients require thorough deliberation taking into account all primary tumour characteristics and findings in the lymph nodes.
As all observational cohort studies, our study has it strengths and weaknesses. The main drawback of this study is that the original articles Annals of Oncology allocation of treatment was not random. Patients in our cohort have been treated according to their tumour and patient characteristics, thus introducing the possibility of treatment bias (or 'bias by indication') that is unsolvable in this study design [26] . In addition, we did not re-examine the pN of patients included in our study. Furthermore, we report on 5-year disease-free survival. For specific subgroups, recurrences might occur later in time. In our study, her2-testing and treatment with trastuzumab was not yet fully implemented. For this specific subgroup of patients, outcomes will have improved.
Since the guideline update in 2008, hormonal therapy has also become available to all patients with ER-or PgR-positive tumours. Our major strength is the large size, the populationbased character and the fact that we have included all breast cancer patients with axillary node-negative disease, ITC or micrometastases in our cohort, reflecting the actual diagnosis, treatment and prognosis of breast cancer patients in the Netherlands. All patients were staged according to the 6th edition of the TNM and treated according to the Dutch national guidelines. Most of the studies have currently reported on minimal lymph node involvement, combining ITC and micrometastases in their analyses, while in this study we could disentangle the effects of ITC and micrometastases on prognosis. 
